Sustained GLP-1 receptor agonist therapy is linked to greater improvements in A1c levels than DPP-4 inhibitor therapy in patients with type 2 diabetes, a Danish real-world analysis shows.
Medscape News UK
Source link : https://www.medscape.com/viewarticle/glp-1-vs-dpp-4-meds-which-better-diabetes-control-2026a10006d6?src=rss
Author :
Publish date : 2026-03-05 12:00:00
Copyright for syndicated content belongs to the linked Source.
